[1] FENICHEL P, CHEVALIER N. Is testicular germ cell cancer estrogen dependent? The role of endocrine disrupting chemicals [J]. Endocrinology, 2019, 160(12): 2981-2989. doi: 10.1210/en.2019-00486
[2] BALABANIC D, RUPNIK M S, KLEMENCIC A K. Negative impact of endocrine-disrupting compounds on human reproductive health [J]. Reproduction Fertility and Development, 2011, 23(3): 403-416. doi: 10.1071/RD09300
[3] BRAUN J M. Early-life exposure to EDCs: Role in childhood obesity and neurodevelopment [J]. Nature Reviews Endocrinology, 2017, 13(3): 161-173. doi: 10.1038/nrendo.2016.186
[4] FOWLER P A, BELLINGHAM M, SINCLAIR K D, et al. Impact of endocrine-disrupting compounds (EDCs) on female reproductive health [J]. Molecular and Cellular Endocrinology, 2012, 355(2): 231-239. doi: 10.1016/j.mce.2011.10.021
[5] HARRIS H A, KATZENELLENBOGEN J A, KATZENELLENBOGEN B S J E. Characterization of the biological roles of the estrogen receptors, ERα and ERβ, in estrogen target tissues in vivo through the use of an ERα-selective ligand [J]. Endocrinology, 2002(11): 4172-4177.
[6] THOMAS P, DONG J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: A potential novel mechanism of endocrine disruption [J]. The Journal of Steroid Biochemistry and Molecular Biology, 2006, 102(1): 175-179.
[7] PROSSNITZ E R, BARTON M. The G-protein-coupled estrogen receptor GPER in health and disease [J]. Nature Reviews Endocrinology, 2011, 7(12): 715-726. doi: 10.1038/nrendo.2011.122
[8] PROSSNITZ E R, BARTON M. Signaling, physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER [J]. Prostaglandins Other Lipid Mediat, 2009, 89(3-4): 89-97. doi: 10.1016/j.prostaglandins.2009.05.001
[9] WANG C, LI J, YE S, et al. Oestrogen inhibits VEGF expression and angiogenesis in triple-negative breast cancer by activating GPER-1 [J]. Journal of Cancer, 2018, 9(20): 3802-3811. doi: 10.7150/jca.29233
[10] NIRO S, PEREIRA E, PELISSIER M A, et al. The DHEA metabolite 7β-hydroxy-epiandrosterone exerts anti-estrogenic effects on breast cancer cell lines [J]. Steroids, 2012, 77(5): 542-551. doi: 10.1016/j.steroids.2012.01.019
[11] PROSSNITZ E, BARTON M. Estrogen biology: New insights into GPER function and clinical opportunities [J]. Molecular and Cellular Endocrinology, 2014, 389(1): 71-83.
[12] ALBANITO L, MADEO A, LAPPANO R, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17β-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells [J]. Cancer Research, 2007, 67(4): 1859-1866. doi: 10.1158/0008-5472.CAN-06-2909
[13] REVANKAR C M, MITCHELL H D, FIELD A S, et al. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30 [J]. Acs Chemical Biology, 2007, 2(8): 536-544. doi: 10.1021/cb700072n
[14] TSUGAWA Y, HIRAMOTO M. IMAI T. Estrogen induces estrogen receptor α expression and hepatocyte proliferation in late pregnancy [J]. Biochemical & Biophysical Research Communications, 2019, 511(3): 592-596.
[15] PROSSNITZ E R. GPER modulators: Opportunity nox on the heels of a class akt [J]. The Journal of Steroid Biochemistry and Molecular Biology, 2018, 176: 73-81. doi: 10.1016/j.jsbmb.2017.03.005
[16] CAO L Y, REN X M, LI C H, et al. Bisphenol AF and bisphenol B exert higher estrogenic effects than bisphenol A via G protein-coupled estrogen receptor pathway [J]. Environmental Science & Technology, 2017, 51(19): 11423-11430.
[17] RUSSO D P, ZORN K M, CLARK A M, et al. Comparing multiple machine learning algorithms and metrics for estrogen receptor binding prediction [J]. Molecular Pharmaceutics, 2018, 15(10): 4361-4370. doi: 10.1021/acs.molpharmaceut.8b00546
[18] GRISONI F, CONSONNI V. BALLABIO D. Machine learning consensus to predict the binding to the androgen receptor within the compara project [J]. Journal of Chemical Information and Modeling, 2019, 59(5): 1839-1848. doi: 10.1021/acs.jcim.8b00794
[19] SHEFFIELD T, JUDSON R. Ensemble QSAR modeling to predict multispecies fish toxicity lethal concentrations and points of departure [J]. Environmental Science & Technology, 2019, 53(21): 12793-12802.
[20] WANG Z, CHEN J, HONG H. Applicability domains enhance application of PPARγ agonist classifiers trained by drug-like compounds to environmental chemicals [J]. Chemical Research in Toxicology, 2020, 33(6): 1382-1388. doi: 10.1021/acs.chemrestox.9b00498
[21] ARNATT C K, ZHANG Y. G protein-coupled estrogen receptor (GPER) agonist dual binding mode analyses toward understanding of its activation mechanism: a comparative homology modeling approach [J]. Molecular Informmatics, 2013, 32(7): 647-658. doi: 10.1002/minf.201200136
[22] WANG D, HU L, ZHANG G, et al. G protein-coupled receptor 30 in tumor development [J]. Endocrine, 2010, 38(1): 29-37. doi: 10.1007/s12020-010-9363-z
[23] BARTON M, PROSSNITZ E R. Emerging roles of GPER in diabetes and atherosclerosis [J]. Trends in Endocrinology & Metabolism, 2015, 26(4): 185-192.
[24] PROSSNITZ E, ARTERBURN J. International union of basic and clinical pharmacology. XCVII. G protein-coupled estrogen receptor and its pharmacologic modulators [J]. Pharmacological Reviews, 2015, 67(3): 505-540. doi: 10.1124/pr.114.009712
[25] KHAN S U, AHEMAD N, CHUAH L H, et al. Sequential ligand and structure-based virtual screening approach for the identification of potential G protein-coupled estrogen receptor-1 (GPER-1) modulators [J]. Rsc Advances, 2019, 9(5): 2525-2538. doi: 10.1039/C8RA09318K
[26] LAPPANO R, ROSANO C, PISANO A, et al. A calixpyrrole derivative acts as an antagonist to GPER, a G-protein coupled receptor: mechanisms and models [J]. Disease models & mechanisms, 2015, 8(10): 1237-1246.
[27] SARMIENTO V, SANCHEZ T R, ULLOA A M, et al. Synthesis of novel (-) -epicatechin derivatives as potential endothelial GPER agonists: Evaluation of biological effects [J]. Bioorganic & Medicinal Chemistry Letters, 2018, 28(4): 658-663.
[28] CAO L Y, REN X M, YANG Y, et al. Hydroxylated polybrominated biphenyl ethers exert estrogenic effects via non-genomic G protein-coupled estrogen receptor mediated pathways [J]. Environmental Health Perspectives, 2018, 126(5): 057005. doi: 10.1289/EHP2387
[29] O’DEA A, SONDERGARD C, SWEENEY P, et al. A series of indole-thiazole derivatives act as GPER agonists and inhibit breast cancer cell growth [J]. Acs Medicinal Chemistry Letters, 2018, 9(9): 901-906. doi: 10.1021/acsmedchemlett.8b00212
[30] ALBANITO L, LAPPANO R, MADEO A, et al. Effects of atrazine on estrogen receptor α and G protein-coupled receptor 30-mediated signaling and proliferation in cancer cells and cancer-associated fibroblasts [J]. Environmental Health Perspectives, 2015, 123(5): 493-499. doi: 10.1289/ehp.1408586
[31] REVANKAR C M, BOLOGA C G, PEPERMANS R A, et al. A selective ligand for estrogen receptor proteins discriminates rapid and genomic signaling [J]. Cell Chemical Biology, 2019, 26(12): 1692-1702. doi: 10.1016/j.chembiol.2019.10.009
[32] CIRILLO F, LAPPANO R, BRUNO L, et al. AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs) [J]. Journal of Experimental & Clinical Cancer Research, 2019, 38(1): 335-353.
[33] ALDO M U, DAVID M L, ERNESTO B R, et al. The effects of (-)-epicatechin on endothelial cells involve the G protein-coupled estrogen receptor (GPER) [J]. Pharmacological Research, 2015, 100: 309-320. doi: 10.1016/j.phrs.2015.08.014
[34] MAGGIOLINI M, SANTOLLA M, AVINO S, et al. Identification of two benzopyrroloxazines acting as selective GPER antagonists in breast cancer cells and cancer-associated fibroblasts [J]. Future medicinal chemistry, 2015, 7(4): 437-448. doi: 10.4155/fmc.15.3
[35] ROSANO C, PONASSI M, SANTOLLA M F, et al. Macromolecular modelling and docking simulations for the discovery of selective GPER ligands [J]. The AAPS Journal, 2016, 18(1): 41-46. doi: 10.1208/s12248-015-9844-3
[36] DELEON C, WANG H, GUNN J, et al. A novel GPER antagonist protects against the formation of estrogen-induced cholesterol gallstones in female mice [J]. Journal of Lipid Research, 2020, 61(5): 767-777. doi: 10.1194/jlr.RA119000592
[37] NAYAK T K, DENNIS M K, RAMESH C, et al. Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111in-labeled nonsteroidal imaging agents [J]. ACS Chemical Biology, 2010, 5(7): 681-690. doi: 10.1021/cb1000636
[38] LUO L J, LIU F, LIN Z K, et al. Genistein regulates the IL-1 beta induced activation of MAPKs in human periodontal ligament cells through G protein-coupled receptor 30 [J]. Archives of Biochemistry and Biophysics, 2012, 522(1): 9-16. doi: 10.1016/j.abb.2012.04.007